Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed advanced solid tumor that is not curable by conventional therapy Brain metastases allowed if adequately controlled with radiotherapy PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 60-100% Life expectancy: At least 12 weeks Hematopoietic: WBC at least 3,500/mm^3 Absolute neutrophil count at least 2,000/mm^3 Platelet count at least 100,000/mm^3 Hepatic: SGOT and SGPT no greater than 3 times normal Bilirubin no greater than 2.0 mg/dL Renal: Creatinine no greater than 1.5 mg/dL Creatinine clearance greater than 60 mL/min BUN no greater than 25 mg/dL Cardiovascular: Adequate cardiovascular function No congestive heart failure (New York Heart Association class III or IV heart disease) No angina pectoris AND/OR No significant arrhythmia No myocardial infarction within the past 6 months No clinically significant ischemic cardiac disease currently under treatment No clinically significant conduction system disease in the absence of a pacemaker (e.g., sick sinus syndrome, or second or third degree atrioventricular block) Pulmonary: Adequate pulmonary function No clinical evidence of acute chronic obstructive pulmonary disease FEV1 at least 50% predicted Arterial oxygen tension at least 90% by pulse oximetry and on breathing room air No asthma OR No evidence of more than 20% reversibility in FEV1 with albuterol therapy Other: Not pregnant or nursing Fertile patients must use effective contraception No history of severe adverse reaction to adenosine No uncontrolled medical illness No average daily pain scores of at least 5 on a simple Visual Analogue Self pain assessment (0-10) scale PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics At least 3 weeks since prior radiotherapy and recovered Surgery: Not specified Other: At least 30 days since prior investigational therapy At least 14 days since prior long-term theophylline, dipyridamole, or dipyridamole/aspirin therapy No concurrent long-term theophylline, dipyridamole, or dipyridamole/aspirin therapy No concurrent maintenance anti-anginal drug therapy